While Australians can invest in some excellent local healthcare companies, there are limitations. For instance, they tend to be either single or narrow product device companies, says Monik Kotecha, Insync. Global pharmaceutical companies benefit from ageing demographics By 2005, 10 per cent of global population was aged over 60 By 2050, 22 per cent of […]
global economy
Insync invests in global biotech company Thermo Fisher
Insync Global Titans Fund has invested in global biotechnology company Thermo Fisher Scientific on an attractive free cash flow yield of 5.7 per cent for 2016. Ageing populations, the need for better and broader healthcare access globally, more stringent environmental and testing regulations, along with the rising demand for better healthcare and a cleaner environment […]
Insync Funds Management is a global equity specialist based in Sydney. Key team members own equity in the business and co-invest in the Fund alongside other investors.